BEGIN:VCALENDAR VERSION:2.0 PRODID:-//hacksw/handcal//NONSGML v1.0//EN BEGIN:VEVENT UID:ac38ea68d19e6b6fb785c841cbab73cb DTSTAMP:20260604T045952Z DTSTART:20251001T140000 DTEND:20251001T160000 SUMMARY:Protection from birth: Expanding access to hepatitis B birth dose DESCRIPTION:Protection from birth: Expanding access to hepatitis B birth dose\nWHO estimates that 254 million people were living with chronic hepatitis B infection (HBV) in 2022 and 1.3 million new infections each year. Hepatitis B Birth Dose (HepB-BD) vaccine, given within 24 hours after birth and followed by at least two subsequent doses, is approximately 90% effective at preventing perinatal HBV infection. By the end of 2023, only 17 countries in AFRO had introduced HepB BD; in EMRO, all but 5 countries have introduced the vaccine.\nSince the launch of the Gavi HepB-BD vaccine programme in June 2024, 12 countries have been approved, with introductions planned for 2025 and 2026.\nOn October 1, WHO in collaboration with Gavi and other partners will conduct an interactive webinar to provide information to stakeholders in countries that plan to apply for Gavi support.\nThis webinar will: \n\nShare WHO recommendations, guidance and tools for introducing HepB BD vaccine\nShare the global and regional Triple Elimination goals and targets\nProvide an update on the available Gavi support for countries to introduce HepB BD vaccine, including implications for countries moving into Gavi 6.0.\nAnswer any questions or address concerns of countries/ Gavi teams and alliance partners on the new programme.\n\nInterpretation in French will be available.\nRegister here: https://who.zoom.us/webinar/register/WN_ArPqP2JCTLeT3WA-0zYSOA#/registration X-ALT-DESC;FMTTYPE=text/html:\n\n\n\n\n\n\n\n\n

Protection from birth: Expanding access to hepatitis B birth dose


WHO estimates that 254 million people were living with chronic hepatitis B infection (HBV) in 2022 and 1.3 million new infections each year. Hepatitis B Birth Dose (HepB-BD) vaccine, given within 24 hours after birth and followed by at least two subsequent doses, is approximately 90% effective at preventing perinatal HBV infection. By the end of 2023, only 17 countries in AFRO had introduced HepB BD; in EMRO, all but 5 countries have introduced the vaccine.


Since the launch of the Gavi HepB-BD vaccine programme in June 2024, 12 countries have been approved, with introductions planned for 2025 and 2026.


On October 1, WHO in collaboration with Gavi and other partners will conduct an interactive webinar to provide information to stakeholders in countries that plan to apply for Gavi support.


This webinar will: 



Interpretation in French will be available.


Register here: https://who.zoom.us/webinar/register/WN_ArPqP2JCTLeT3WA-0zYSOA#/registration

\n\n\n LOCATION: END:VEVENT END:VCALENDAR